The integration of pHLA binding and pHLA-TCR analysis effectively improves the precision of insilico neoantigen prioritization, potentially enhancing personalized immunotherapies for colorectal cancer.

In vivo modeling of neoantigen-restricted heterogeneity shows that clonal expression of neoantigens enhances anti-tumor T cell responses by increasing the stimulatory capacity of dendritic cells in the lymph node.

ePAC, a novel cancer vaccine utilizing a mammalian-derived virus-like particle to co-deliver neoantigens and CpG-ODN, demonstrates strong antitumor efficacy in mouse models.

Natural antibodies play a fundamental role in anti-cancer immunity.

A new, high-throughput in vivo MHC-I peptide minigene library platform shows that the naive immune system cannot eliminate cells presenting immunogenic antigens found at low frequencies within a growing tumor.

Amino acid codon degeneracy indicates antigen-specific selection of the T cell receptors and is predictive of cancer immunotherapy outcomes.

An amino acid dimorphism in HLA-C with an established impact on natural killer cell receptors plays an unexpected and significant role in T cell receptor recognition of HLA-C with relevance for tumor immunity.

Tumors escape killing by the immune system through generating transient spatial cell-in-cell structures that are impenetrable to cytotoxic compounds including lytic granules and chemotherapy.